Citizens JMP raised the firm’s price target on Privia Health (PRVA) to $30 from $29 and keeps an Outperform rating on the shares. The firm upped estimates on the company’s announcement of Medicare Shared Savings Program savings. Privia lifted its 2025 EBITDA guidance to $113M-$116M from the prior “above the high end” of its previous guidance of $105M-$110M, the analyst tells investors in a research note. Citizens believes the company is well positioned to deliver another consistent year of shared savings generation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health Group: Strong Buy Rating Amid Impressive MSSP Performance and Growth Potential
- Privia Health’s Earnings Call Highlights Robust Growth
- Privia Health price target lowered to $35 from $36 at Piper Sandler
- Privia Health Group: Strong Performance and Promising Outlook Justify Buy Rating
- Privia Health Reports Strong Q2 2025 Financial Results